Literature DB >> 20048700

HIV-1-specific antibody responses during acute and chronic HIV-1 infection.

Georgia D Tomaras1, Barton F Haynes.   

Abstract

PURPOSE OF REVIEW: The humoral immune response to HIV-1 throughout infection is comprised of complex mixtures of antibody isotypes with numerous HIV-1 specificities. However, unlike antibody responses to most infections, protective antibody responses are delayed and do not arise until long after HIV-1 latency is established. We review recent data on HIV-1-specific antibody isotypes induced following HIV-1 transmission: to understand the effects of HIV-1 on B cell and T cell effector responses, to understand the timing of the rise and fall of different anti-HIV-1 antibodies and to understand how antibodies could contribute to protective immunity if they were either pre-existing or elicited immediately after HIV-1 transmission. RECENT
FINDINGS: Studies of the earliest events following infection by the transmitted/founder virus have recently revealed that early destruction of B cell generative microenvironments may be responsible for delay of potentially protective anti-HIV-1 antibody responses. Unlike the initial CD8 T cell response to HIV-1, the initial induced antibody response is usually ineffective in controlling virus replication during acute HIV-1 infection.
SUMMARY: The antibody isotypes and specificities elicited during HIV-1 infection can provide a window into deciphering the detrimental effects of HIV-1 on B cell and T cell responses. Additionally, further characterization of the virus inhibitory capabilities of anti-HIV-1 antibody isotypes can define the spectrum of potential protective HIV-1 antibodies that could be readily elicited by experimental vaccines and adjuvants.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20048700      PMCID: PMC3133462          DOI: 10.1097/COH.0b013e32832f00c0

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  74 in total

1.  Neutralizing inter-clade cross-reactivity of HIV-1 V1/V2-specific secretory immunoglobulin A in Colombian and French cohorts.

Authors:  Viviana Granados-Gonzalez; Leidy Diana Piedrahita; Marlen Martinez-Gutierrez; Philip Lawrence; Henia Saoudin; Ximena Zapata; Frederic Lucht; Abraham Pinter; Christian Genin; Silvio Urcuqui-Inchima; Serge Riffard
Journal:  AIDS       Date:  2009-10-23       Impact factor: 4.177

2.  High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.

Authors:  Katie L Davis; Elin S Gray; Penny L Moore; Julie M Decker; Aidy Salomon; David C Montefiori; Barney S Graham; Michael C Keefer; Abraham Pinter; Lynn Morris; Beatrice H Hahn; George M Shaw
Journal:  Virology       Date:  2009-03-18       Impact factor: 3.616

3.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Authors:  Johannes F Scheid; Hugo Mouquet; Niklas Feldhahn; Michael S Seaman; Klara Velinzon; John Pietzsch; Rene G Ott; Robert M Anthony; Henry Zebroski; Arlene Hurley; Adhuna Phogat; Bimal Chakrabarti; Yuxing Li; Mark Connors; Florencia Pereyra; Bruce D Walker; Hedda Wardemann; David Ho; Richard T Wyatt; John R Mascola; Jeffrey V Ravetch; Michel C Nussenzweig
Journal:  Nature       Date:  2009-03-15       Impact factor: 49.962

4.  Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41.

Authors:  Lautaro G Perez; Matthew R Costa; Christopher A Todd; Barton F Haynes; David C Montefiori
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

5.  A method for identification of HIV gp140 binding memory B cells in human blood.

Authors:  Johannes F Scheid; Hugo Mouquet; Niklas Feldhahn; Bruce D Walker; Florencia Pereyra; Emily Cutrell; Michael S Seaman; John R Mascola; Richard T Wyatt; Hedda Wardemann; Michel C Nussenzweig
Journal:  J Immunol Methods       Date:  2008-12-25       Impact factor: 2.303

Review 6.  B cells in HIV infection and disease.

Authors:  Susan Moir; Anthony S Fauci
Journal:  Nat Rev Immunol       Date:  2009-04       Impact factor: 53.106

7.  Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.

Authors:  Melissa D Simek; Wasima Rida; Frances H Priddy; Pham Pung; Emily Carrow; Dagna S Laufer; Jennifer K Lehrman; Mark Boaz; Tony Tarragona-Fiol; George Miiro; Josephine Birungi; Anton Pozniak; Dale A McPhee; Olivier Manigart; Etienne Karita; André Inwoley; Walter Jaoko; Jack Dehovitz; Linda-Gail Bekker; Punnee Pitisuttithum; Robert Paris; Laura M Walker; Pascal Poignard; Terri Wrin; Patricia E Fast; Dennis R Burton; Wayne C Koff
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

8.  Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers.

Authors:  Olivier Lambotte; Guido Ferrari; Christiane Moog; Nicole L Yates; Hua-Xin Liao; Robert J Parks; Charles B Hicks; Kouros Owzar; Georgia D Tomaras; David C Montefiori; Barton F Haynes; Jean-François Delfraissy
Journal:  AIDS       Date:  2009-05-15       Impact factor: 4.177

Review 9.  Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

Authors:  Leonidas Stamatatos; Lynn Morris; Dennis R Burton; John R Mascola
Journal:  Nat Med       Date:  2009-08       Impact factor: 53.440

10.  Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection.

Authors:  Marc C Levesque; M Anthony Moody; Kwan-Ki Hwang; Dawn J Marshall; John F Whitesides; Joshua D Amos; Thaddeus C Gurley; Sallie Allgood; Benjamin B Haynes; Nathan A Vandergrift; Steven Plonk; Daniel C Parker; Myron S Cohen; Georgia D Tomaras; Paul A Goepfert; George M Shaw; Jörn E Schmitz; Joseph J Eron; Nicholas J Shaheen; Charles B Hicks; Hua-Xin Liao; Martin Markowitz; Garnett Kelsoe; David M Margolis; Barton F Haynes
Journal:  PLoS Med       Date:  2009-07-07       Impact factor: 11.069

View more
  87 in total

1.  Rapid HIV Progression Is Associated with Extensive Ongoing Somatic Hypermutation.

Authors:  Ben S Wendel; Yajing Fu; Chenfeng He; Stefany M Hernandez; Mingjuan Qu; Zining Zhang; Yongjun Jiang; Xiaoxu Han; Junjie Xu; Haibo Ding; Ning Jiang; Hong Shang
Journal:  J Immunol       Date:  2020-06-26       Impact factor: 5.422

Review 2.  Strategies for eliciting HIV-1 inhibitory antibodies.

Authors:  Georgia D Tomaras; Barton F Haynes
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

3.  Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection.

Authors:  Nicole L Yates; Judith T Lucas; Tracy L Nolen; Nathan A Vandergrift; Kelly A Soderberg; Kelly E Seaton; Thomas N Denny; Barton F Haynes; Myron S Cohen; Georgia D Tomaras
Journal:  AIDS       Date:  2011-11-13       Impact factor: 4.177

4.  Viral control in chronic HIV-1 subtype C infection is associated with enrichment of p24 IgG1 with Fc effector activity.

Authors:  Amy W Chung; Jenniffer M Mabuka; Bongiwe Ndlovu; Anna Licht; Hannah Robinson; Yathisha Ramlakhan; Musie Ghebremichael; Tarylee Reddy; Philip J R Goulder; Bruce D Walker; Thumbi Ndung'u; Galit Alter
Journal:  AIDS       Date:  2018-06-19       Impact factor: 4.177

5.  Can HIV p24 be a suitable scaffold for presenting Env antigens?

Authors:  Luigi Buonaguro; Maria Tagliamonte; Maria Lina Tornesello; Franco M Buonaguro
Journal:  Clin Vaccine Immunol       Date:  2011-09-07

Review 6.  T-bet-expressing B cells during HIV and HCV infections.

Authors:  James J Knox; David E Kaplan; Michael R Betts
Journal:  Cell Immunol       Date:  2017-07-11       Impact factor: 4.868

7.  T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response.

Authors:  James J Knox; Marcus Buggert; Lela Kardava; Kelly E Seaton; Michael A Eller; David H Canaday; Merlin L Robb; Mario A Ostrowski; Steven G Deeks; Mark K Slifka; Georgia D Tomaras; Susan Moir; M Anthony Moody; Michael R Betts
Journal:  JCI Insight       Date:  2017-04-20

8.  Workshop summary: Novel biomarkers for HIV incidence assay development.

Authors:  Usha K Sharma; Marco Schito; Alex Welte; Christine Rousseau; Joseph Fitzgibbon; Brandon Keele; Stuart Shapiro; Andrew McMichael; David N Burns
Journal:  AIDS Res Hum Retroviruses       Date:  2012-02-24       Impact factor: 2.205

9.  Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity.

Authors:  John Pietzsch; Johannes F Scheid; Hugo Mouquet; Michael S Seaman; Christopher C Broder; Michel C Nussenzweig
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

10.  Characterization of plasmablasts in the blood of HIV-infected viremic individuals: evidence for nonspecific immune activation.

Authors:  Clarisa M Buckner; Susan Moir; Jason Ho; Wei Wang; Jacqueline G Posada; Lela Kardava; Emily K Funk; Amy K Nelson; Yuxing Li; Tae-Wook Chun; Anthony S Fauci
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.